Back

Calcium channel blocker and outcomes in patients with heart failure and mildly reduced or preserved ejection fraction

22 May 2023 (11:00 - 11:30)
Organised by: Logo
Congress Presentation Part of: Chronic heart failure - treatment 3 Pharmacotherapy HFA Premium Access Heart Failure 2023 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Shingo Matsumoto

Tokai University, Tokyo (Japan)

4 More presentations in this session

Presentation thumbnail
Efficacy of dapagliflozin according to heart rate in patients with heart failure: a patient-level pooled analysis of DAPA-HF and DELIVER
Doctor T. Kondo (Nagoya, JP)
Abstract Slides
Presentation thumbnail
Patient characteristics, outcomes, and effects of dapagliflozin according to the duration of heart failure: a prespecified analysis of the DELIVER trial
Doctor T. Kondo (Nagoya, JP)
Abstract Slides
Presentation thumbnail
Medium term improvement in left ventricular systolic function following CRT pacemaker implantation indicates additional defibrillator component may not be necessary
Doctor H. Shabbir (Blackburn, GB)
Abstract Slides
Presentation thumbnail
Left bundle branch block cardiomyopathy: an intriguing and defiant entity from diagnosis to treatment
Ms C. Oliveira (Porto, PT)
Abstract Slides

Access the full session

Session thumbnail
Chronic heart failure - treatment 3

The Event

Event poster

Heart Failure 2023

22 May 2023 11:00 CET
You may be interested in
thumbnail
Congress Presentation
Association between calcium channel blockers prescription and outcome according to left ventricular ejection fraction: data from a real-world heart failure population
thumbnail
Congress Presentation
Calcium channel blockers in hypertensive heart failure: mortality outcomes and subgroup analysis
thumbnail
Congress Presentation
Statin therapy in chronic heart failure with reduced ejection fraction: a post-hoc analysis of T.O.S.C.A. Registry

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources